Literature DB >> 32072403

Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas.

Mojdeh Mahdiannasser1, Vahid Haghpanah2,3, Elia Damavandi4,5, Majid Kabuli1, Seyed Mohammad Tavangar6, Bagher Larijani2, Mohsen Ghadami7,8,9.   

Abstract

FSCN1 gene encodes an actin-bundling protein, FSCN1, which is involved in formation of actin-based structures that contribute to cell migration. High levels of FSCN1 expression is observed in cells with extended membranes and protrusions. Moreover, up-regulation of FSCN1 has been reported in several epithelial carcinomas. Therefore, FSCN1 is thought to play a role in cell movement and invasion. However, the mechanism behind FSCN1 up-regulation is not known. We investigated the expression of FSCN1 using immunohistochemistry. Methylation-specific PCR was adopted to analyze the methylation status of FSCN1 promoter as a potential regulatory mechanism in FSCN1 expression. The samples included papillary thyroid carcinoma, follicular thyroid carcinoma and goiter samples (controls). Methylation of FSCN1 promoter was observed in 50% of follicular, 48.6% of papillary and 60% of controls. The promoter was unmethylated in 16.7% of follicular samples, 5.7% of papillary samples and 26.7% of controls. In the remaining 33.3% of follicular and 45.7% of papillary samples as well as 13.3% of controls, both methylated and unmethylated alleles were amplified, a condition referred to as semi-methylation. The results showed that FSCN1 promoter was significantly hypomethylated in papillary cases while the methylation status was not significantly altered in follicular cases. On the other hand, FSCN1 was expressed in only nine papillary samples. Regarding protein expression and methylation status, we suggest that hypomethylation of FSCN1 promoter in papillary thyroid carcinoma does not lead to overexpression of FSCN1 and that there might be other regulatory mechanisms involved in FSCN1 up-regulation.

Entities:  

Keywords:  FSCN1; Immunohistochemistry; Methylation; Promoter; Thyroid cancer

Mesh:

Substances:

Year:  2020        PMID: 32072403     DOI: 10.1007/s11033-020-05315-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

Review 1.  Thyroid cancer.

Authors:  Maria E Cabanillas; David G McFadden; Cosimo Durante
Journal:  Lancet       Date:  2016-05-27       Impact factor: 79.321

2.  Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma.

Authors:  David G McFadden; Dora Dias-Santagata; Peter M Sadow; Kerry D Lynch; Carrie Lubitz; Samuel E Donovan; Zongli Zheng; Long Le; A J Iafrate; Gilbert H Daniels
Journal:  J Clin Endocrinol Metab       Date:  2014-08-22       Impact factor: 5.958

Review 3.  Diagnosis and treatment of patients with thyroid cancer.

Authors:  Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski
Journal:  Am Health Drug Benefits       Date:  2015-02

Review 4.  Papillary thyroid carcinoma: an update.

Authors:  Virginia A LiVolsi
Journal:  Mod Pathol       Date:  2011-04       Impact factor: 7.842

Review 5.  The RET oncogene in papillary thyroid carcinoma.

Authors:  Jason D Prescott; Martha A Zeiger
Journal:  Cancer       Date:  2015-03-02       Impact factor: 6.860

6.  Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.

Authors:  Liborio Torregrossa; David Viola; Elisa Sensi; Mirella Giordano; Paolo Piaggi; Cristina Romei; Gabriele Materazzi; Paolo Miccoli; Rossella Elisei; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

Review 7.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

Review 8.  TERT promoter mutations in thyroid cancer.

Authors:  Rengyun Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2016-01-05       Impact factor: 5.678

Review 9.  Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations.

Authors:  Mardiaty Iryani Abdullah; Sarni Mat Junit; Khoon Leong Ng; Jaime Jacqueline Jayapalan; Barani Karikalan; Onn Haji Hashim
Journal:  Int J Med Sci       Date:  2019-02-28       Impact factor: 3.738

10.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07
View more
  1 in total

Review 1.  FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility: a review of its function, mechanism, and clinical significance.

Authors:  Zhongxun Li; Jiao Shi; Nannan Zhang; Xiwang Zheng; Yukun Jin; Shuxin Wen; Wanglai Hu; Yongyan Wu; Wei Gao
Journal:  J Cancer       Date:  2022-05-09       Impact factor: 4.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.